XML 30 R19.htm IDEA: XBRL DOCUMENT v3.19.1
Subsequent Events
3 Months Ended
Mar. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events

12.

Subsequent Events

PTC License Agreement Regulatory Milestone

On May 3, 2019, we received regulatory approval for WAYLIVRA from the European Commission, or EC, for the treatment of adult patients with genetically confirmed familial chylomicronemia syndrome, or FCS, in the EU. As a result we will be due a license fee of $6.0 million from PTC as part of our PTC License Agreement discussed in Note 8, Collaboration and License Agreement with PTC Therapeutics, of which we will pay Ionis $3.0 million as a sublicense fee related to the Cardiometabolic License Agreement.